Simponi Drug Interactions

Overview: SIMPONI can be used in combination with methotrexate in adult patients with RA, AS or PsA. Specific drug interaction studies have not been conducted with SIMPONI.
Drug-Drug Interactions: Concurrent Use of SIMPONI with other Biological Therapeutics: The combination of SIMPONI with other biological therapeutics used to treat the same conditions as SIMPONI, including anakinra or abatacept is not recommended (see Precautions).
Live Vaccines/Therapeutic Infectious Agents: Live vaccines should not be given concurrently with SIMPONI (see Immune: Immunizations under Precautions).
Therapeutic infectious agents should not be given concurrently with SIMPONI.
Methotrexate: Although concomitant use of methotrexate (MTX) results in higher steady-state trough concentrations of SIMPONI and reduction of its apparent clearance (approximately by 36%) in patients with RA, PsA, or AS, the data do not suggest the need for dose adjustment of either SIMPONI or methotrexate (see Pharmacology: Pharmacokinetics under Actions).
Cytochrome P450 Substrates: The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as golimumab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of SIMPONI in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Drug-Herb Interactions: Interactions with herbal products have not been established.